The Aggrenox blood thinner antitrust class action settlement resulted in a $54 million recovery approved in July 2018 for consumers and healthcare plans that overpaid for the drug due to an alleged pay-for-delay scheme. Boehringer Ingelheim, the manufacturer of Aggrenox (aspirin and dipyridamole), allegedly paid Teva Pharmaceutical and Barr Pharmaceuticals approximately $120 million over seven years to keep a generic version off the market, delaying competition until 2015. This settlement compensated indirect purchasers—including employers, unions, and health plans—who paid inflated prices while the drug remained under patent protection longer than it should have.
The case demonstrates how pharmaceutical companies can use patent litigation settlements not as dispute resolutions but as anticompetitive tools. In 2007, Barr Pharmaceuticals sued Boehringer Ingelheim over patent infringement after attempting to bring a generic version to market, but instead of letting the lawsuit proceed to trial, the two companies allegedly reached a side agreement that kept the generic blocked for years. This type of settlement, called a “pay-for-delay” arrangement, has drawn increased scrutiny from federal regulators and courts as a form of anticompetitive conduct that ultimately harms consumers and the healthcare system.
Table of Contents
- What Is a “Pay-for-Delay” Settlement in Pharmaceutical Litigation?
- The Aggrenox Settlement Structure and Fund Distribution
- How the Patent Dispute Led to Alleged Anticompetitive Conduct
- Who Was Harmed and What Did They Recover?
- The Limitations and Challenges of the Settlement Process
- The Broader Context of Pharmaceutical Antitrust Enforcement
- What Happened After the Settlement and Current Status
- Conclusion
What Is a “Pay-for-Delay” Settlement in Pharmaceutical Litigation?
A pay-for-delay settlement occurs when a brand-name drug manufacturer pays a generic competitor to delay or abandon its entry into the market. Unlike a normal patent settlement where one party wins or both agree to share a market, pay-for-delay arrangements involve a reverse payment—cash flowing from the brand to the generic company—in exchange for staying out of the market. The Aggrenox case is a textbook example: Boehringer paid Barr and Teva an estimated $120 million over seven years to maintain Aggrenox’s market exclusivity, preventing generic competition that would have driven down prices. These settlements reduce competition artificially and allow brand-name manufacturers to maintain higher prices longer than they otherwise could.
Consumers and health plans bear the cost through higher premiums and out-of-pocket expenses. For example, if Aggrenox’s generic version had entered the market in 2008 or 2009 when Barr first attempted it, prices would have dropped significantly, potentially saving the healthcare system hundreds of millions of dollars over the years that followed. The Federal Trade Commission has challenged pay-for-delay arrangements as anticompetitive since the 1990s, but these settlements remained partially legal until the Supreme Court’s 2013 decision in FTC v. Actavis clarified that such arrangements could violate antitrust law. The Aggrenox settlement predated full legal clarity on this issue, which is why the case took years to resolve and why both the direct purchaser and indirect purchaser settlements had to be negotiated separately.
The Aggrenox Settlement Structure and Fund Distribution
The Aggrenox antitrust litigation actually resulted in two separate settlements: a $146 million settlement with direct purchasers (pharmacies, wholesalers, and hospitals that bought directly from the manufacturer) approved in a prior year, and the $54 million settlement with indirect purchasers (health plans, employers, unions, and other third-party payers) approved in July 2018. The indirect purchaser fund was further adjusted to $50,229,193 after accounting for class member exclusions and administrative costs. Class counsel received approximately $16,743,064 in fees, representing roughly one-third of the indirect purchaser fund—a percentage common in antitrust class actions but substantial nonetheless. The settlement covers anyone who, as an indirect purchaser, paid for Aggrenox between 2001 and 2015, when the generic version finally entered the market. This includes employees covered by self-insured health plans, members of union health funds, and beneficiaries of government health programs that purchased Aggrenox.
The claims process requires documentation showing that you or your plan actually purchased or paid for Aggrenox during the relevant period. Without proof of purchase, you cannot receive a distribution from the settlement fund. It’s important to note that the settlement fund, while substantial in absolute terms, must be divided among potentially thousands of claimants across the entire United States. Individual payments typically ranged from modest amounts to several hundred dollars, depending on the quantity of Aggrenox purchased and the number of valid claims filed. The settlement does not provide windfalls to individual consumers; instead, it represents partial compensation for overpayment due to the prolonged absence of generic competition.
How the Patent Dispute Led to Alleged Anticompetitive Conduct
In 2007, Barr Pharmaceuticals filed a patent infringement lawsuit against Boehringer Ingelheim, seeking to challenge the validity of Boehringer’s patents on Aggrenox and establish the right to sell a generic version. Patent litigation between generic and brand manufacturers is common and legally encouraged—it allows generic competitors to challenge questionable patents and get products to market faster. However, instead of litigating the case to conclusion, the parties reached a settlement in which Boehringer allegedly paid Barr (later acquired by Teva) to drop its patent challenge and delay the generic launch. The allegation is that Boehringer’s payment to Teva-Barr served no purpose other than to suppress competition. If Barr had won the lawsuit, it would have launched the generic immediately at no cost.
If Boehringer had won, Barr would have paid nothing. The fact that Boehringer paid Barr hundreds of millions of dollars to abandon the case suggests the payment was compensation for staying out of the market, not a legitimate settlement of disputed patent validity. This distinguishes the Aggrenox case from normal patent settlements where one party’s legal rights are clarified. The delay in generic entry—from Barr’s initial attempt around 2007-2008 until the generic finally launched in 2015—allowed Boehringer to charge brand prices for seven additional years. During that period, Aggrenox typically cost several dollars per pill, compared to a few cents per pill for the generic equivalent available in other countries. This price difference meant that patients with copays paid more, employers paid more in health insurance costs, and government programs like Medicare and Medicaid paid more per dose.
Who Was Harmed and What Did They Recover?
The settlement compensated three categories of purchasers: direct purchasers (pharmacies and wholesalers), direct patient purchasers (individuals who bought Aggrenox out of pocket), and indirect purchasers (health plans and third-party payers). Each group was treated separately because antitrust law recognizes that different parties in the distribution chain may be harmed differently by anticompetitive conduct. Direct purchasers faced pressure from the manufacturer’s pricing; indirect purchasers and patients faced higher copays and deductibles. A key challenge in antitrust settlements is allocating the recovery among multiple harmed parties. The direct purchaser settlement of $146 million went to the companies that bought directly from Boehringer—entities with sophisticated purchasing departments that negotiated with manufacturers. The indirect purchaser settlement of $54 million was allocated to health plans and third-party payers.
Individual consumers who paid copays had limited ability to recover because they are far down the distribution chain and difficult to identify. This creates an imbalance: the entities most removed from the actual manufacturing and pricing decision often receive the largest portions of settlements, while consumers who directly overpaid out of pocket receive little or nothing. For health plans and employers, the settlement provided compensation for premium increases driven by Aggrenox’s inflated cost. Larger plans with claims data showing significant Aggrenox purchases received larger distributions. Smaller plans and self-insured employers without detailed claims documentation faced challenges in proving their purchases and receiving their fair share. The comparison is instructive: a Fortune 500 company with detailed pharmacy claims data could receive hundreds of thousands of dollars, while a small employer with spotty records might receive nothing.
The Limitations and Challenges of the Settlement Process
One significant limitation of the Aggrenox settlement is that it only compensates those who can document their purchases during the 2001-2015 period. Health plans that have since merged, been acquired, or dissolved faced challenges in filing claims because successor entities had to locate historical purchase records. Many smaller employers self-insured at the time but now obtain coverage through larger carriers, making it difficult to trace the original purchases back to the settling entity. This documentation requirement excluded legitimate purchasers who could not locate sufficient proof of their Aggrenox spending. Another limitation is that the settlement, while large in headline terms, was negotiated years after the alleged anticompetitive conduct began. Inflation eroded the real value of the recovery—a dollar recovered in 2018 is worth less than a dollar paid in premium overages in 2007 or 2008.
Moreover, the settlement does not include interest or attorney fees compensation for the extensive litigation required to prove the antitrust violation. Class counsel received approximately one-third of the fund, a percentage that reflects the complexity of proving pharmaceutical antitrust violations but that also reduces the amount available to compensate actual victims. A critical warning: the availability of settlement proceeds is time-limited. Most antitrust settlements require that claims be filed within a specific deadline, often 12-24 months after the settlement is approved. If a health plan or employer misses the filing deadline, it loses its recovery opportunity entirely. Additionally, some settlement funds reserve the right to revert unclaimed money to the defendant if claims fall below a certain threshold, creating a perverse incentive to encourage robust claims filing. Entities that believe they purchased Aggrenox during the relevant period should verify their eligibility and file claims promptly.
The Broader Context of Pharmaceutical Antitrust Enforcement
The Aggrenox case is part of a larger trend of antitrust enforcement against pharmaceutical pay-for-delay arrangements. The Federal Trade Commission has pursued dozens of similar cases since the 1990s, including settlements involving drugs like Cephalexin, Doxycycline, and numerous others. Each case involves a similar pattern: a brand manufacturer facing generic competition pays the generic competitor to stay out of the market, preserving monopoly pricing. The cumulative harm from these arrangements across the entire pharmaceutical industry is estimated in the billions of dollars annually.
Federal antitrust authorities have made pharmaceutical pay-for-delay cases a priority because they directly increase healthcare costs for consumers, employers, and government payers. Unlike other types of antitrust violations, pay-for-delay arrangements have a transparent and quantifiable impact: generic drugs are typically 80-90% cheaper than brand equivalents. When a brand company pays to prevent a generic launch, the entire healthcare system overpays. The Aggrenox settlement acknowledged this harm by compensating multiple classes of purchasers, setting a precedent for similar cases.
What Happened After the Settlement and Current Status
The Aggrenox settlement was fully approved by the U.S. District Court for the District of Connecticut in July 2018, making it enforceable and final. The settlement fund was established and distributed to approved claimants over the following months and years. By 2020, most eligible claimants had received their distributions, though some claims remained under review or in dispute.
The case is now concluded, and no further recovery is available from this settlement. For healthcare stakeholders, the Aggrenox settlement serves as a reminder to monitor pharmaceutical pricing and patent litigation outcomes. When a brand manufacturer faces generic competition, a quick settlement favoring the brand is often a sign of anticompetitive conduct. Organizations purchasing pharmaceuticals should maintain detailed records of purchases and pricing to support future settlement claims. Additionally, the settlement demonstrates that even substantial recoveries—$54 million sounds large—are often inadequate to fully compensate all harmed parties when divided across the entire healthcare system.
Conclusion
The Aggrenox blood thinner antitrust class action settlement recovered $54 million for indirect purchasers harmed by an alleged pay-for-delay scheme in which Boehringer Ingelheim paid Teva-Barr approximately $120 million to delay generic competition. The settlement approved in July 2018 represents partial compensation for the inflated prices consumers and health plans paid during the seven-year delay of generic entry, though individual recoveries were modest due to the large number of potential claimants and the complexity of proving purchase history.
If you believe your health plan, employer, or organization purchased Aggrenox between 2001 and 2015, verify your eligibility to claim from the settlement fund. However, be aware that most settlement claims are now closed or claim periods have expired. For future pharmaceutical antitrust cases, monitor brand-generic patent settlements carefully, maintain detailed purchase records, and consult with healthcare counsel if you suspect you may be affected by anticompetitive pharmaceutical pricing practices.